121 related articles for article (PubMed ID: 1442212)
1. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
[TBL] [Abstract][Full Text] [Related]
2. Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants.
van der Pluijm G; Löwik CW; de Groot H; Alblas MJ; van der Wee-Pals LJ; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1991 Nov; 6(11):1203-10. PubMed ID: 1839590
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
Green JR; Müller K; Jaeggi KA
J Bone Miner Res; 1994 May; 9(5):745-51. PubMed ID: 8053405
[TBL] [Abstract][Full Text] [Related]
4. Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: application to the study of intravenous 14C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate.
Koopmans SJ; van der Wee-Pals L; Löwik CW; Papapoulos SE
J Bone Miner Res; 1994 Feb; 9(2):241-6. PubMed ID: 8140937
[TBL] [Abstract][Full Text] [Related]
5. In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis.
Most W; Schot L; Ederveen A; van der Wee-Pals L; Papapoulos S; Löwik C
J Bone Miner Res; 1995 Oct; 10(10):1523-30. PubMed ID: 8686508
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.
Boonekamp PM; Löwik CW; van der Wee-Pals LJ; van Wijk-van Lennep ML; Bijvoet OL
Bone Miner; 1987 Feb; 2(1):29-42. PubMed ID: 3504722
[TBL] [Abstract][Full Text] [Related]
7. Zinc is a potent inhibitor of osteoclastic bone resorption in vitro.
Moonga BS; Dempster DW
J Bone Miner Res; 1995 Mar; 10(3):453-7. PubMed ID: 7785467
[TBL] [Abstract][Full Text] [Related]
8. Retinoid-induced bone thinning is caused by subperiosteal osteoclast activity in adult rodents.
Kneissel M; Studer A; Cortesi R; Susa M
Bone; 2005 Feb; 36(2):202-14. PubMed ID: 15780946
[TBL] [Abstract][Full Text] [Related]
9. Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization, and alkaline phosphatase activity in fetal mouse metacarpal bones in culture.
Van Beek E; Van der Wee-Pals L; van de Ruit M; Nijweide P; Papapoulos S; Löwik C
J Bone Miner Res; 1993 Feb; 8(2):191-8. PubMed ID: 8442437
[TBL] [Abstract][Full Text] [Related]
10. Generation and activity of equine osteoclasts in vitro: effects of the bisphosphonate pamidronate (APD).
Gray AW; Davies ME; Jeffcott LB
Res Vet Sci; 2002 Apr; 72(2):105-13. PubMed ID: 12027590
[TBL] [Abstract][Full Text] [Related]
11. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
12. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
[TBL] [Abstract][Full Text] [Related]
13. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
14. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
[TBL] [Abstract][Full Text] [Related]
15. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
[TBL] [Abstract][Full Text] [Related]
16. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
Moran EL; Fornasier TL; Bogoch TR
J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
[TBL] [Abstract][Full Text] [Related]
17. Effects of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts.
Marshall MJ; Wilson AS; Davie MW
J Bone Miner Res; 1990 Sep; 5(9):955-62. PubMed ID: 2281826
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.
Sato M; Grasser W; Endo N; Akins R; Simmons H; Thompson DD; Golub E; Rodan GA
J Clin Invest; 1991 Dec; 88(6):2095-105. PubMed ID: 1661297
[TBL] [Abstract][Full Text] [Related]
19. Morphology of osteoclasts in resorbing fetal rat bone explants: effects of PTH and AIF in vitro.
Wezeman FH; Kuettner KE; Horton JE
Anat Rec; 1979 Jul; 194(3):311-23. PubMed ID: 224732
[TBL] [Abstract][Full Text] [Related]
20. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
